Literature DB >> 27079821

Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.

Kimihide Kusafuka1, Takuya Kawasaki1, Matsuyoshi Maeda2, Koji Yamanegi3, Satoshi Baba4, Yohei Ito5, Hiroshi Inagaki5, Takashi Nakajima1.   

Abstract

AIM: To analyse the clinicopathological features and immunohistochemical characteristics of nine cases of salivary duct carcinoma (SDC) with rhabdoid features (SDCRF), representing a new, extremely rare type of salivary gland malignancy. METHODS AND
RESULTS: We analysed 2511 cases of salivary gland tumour, clinicopathologically and immunohistochemically. The incidence of SDCRF was 0.4%. Eight patients were male. The age of patients ranged from 36 years to 85 years (mean, 61 years). SDC arose from the parotid glands and submandibular gland in six and three cases, respectively. Seven cases appeared as a carcinoma component of carcinoma ex pleomorphic adenoma cases. Six patients died of disease. Histologically, diffuse proliferations of non-coherent large ovoid or polygonal carcinoma cells with eosinophilic cytoplasm and eccentric nuclei were observed in all cases; such cytological characteristics were defined as 'rhabdoid features'. Immunohistochemically, all cases were positive for cytokeratin, gross cystic disease fluid protein-15, androgen receptor, and SMARCB1, seven cases were positive for HER2, and two cases were positive for epidermal growth factor receptor. However, all cases were negative for vimentin and myoepithelial markers. Eight cases showed no or aberrant expression of E-cadherin and β-catenin. The results suggest that SDCRF is an extremely rare subtype of SDC, and not a sarcomatoid variant of SDC. SDCRF is histologically unique, and is positive for SDC markers but negative for vimentin, unlike rhabdoid-type carcinomas arising from other organs.
CONCLUSIONS: The morphogenesis of SDCRF is related to no or aberrant expression of cell-cell adhesion molecules. Therefore, SDCRF could be a salivary counterpart to pleomorphic lobular breast carcinoma.
© 2016 The Authors. Histopathology published by John Wiley & Sons Ltd.

Entities:  

Keywords:  E-cadherin; mammary lobular carcinoma; rhabdoid features; salivary duct carcinoma; β-catenin

Mesh:

Substances:

Year:  2016        PMID: 27079821     DOI: 10.1111/his.12987

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

2.  Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?

Authors:  Lisa M Rooper; Jeffrey Gagan; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-07-06

3.  Signet Ring Cell Differentiation in Salivary Duct Carcinoma with Rhabdoid Features: Report of Three Cases and Literature Review.

Authors:  Mayumi Akaki; Akira Ishihara; Kentaro Nagai; Hidekazu Naono; Kenichi Taguchi; Hidetaka Yamamoto; Hiroyuki Tanaka; Hiroaki Kataoka
Journal:  Head Neck Pathol       Date:  2020-06-02

4.  Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report.

Authors:  Koichiro Wasano; Kouhei Sakurai; Taiji Kawasaki; Kimihide Kusafuka; Masao Kasahara; Naoki Kondo; Ken-Ichi Inada; Kaoru Ogawa
Journal:  Rare Tumors       Date:  2018-09-19

5.  Mammary Lobular Carcinoma-Like Salivary Gland Carcinoma: Report of a Rare Case.

Authors:  Li Lei; Eric Van Staalduinen; Megan Troxell; Michael G Ozawa; Michael Zeineh; Gerald Berry
Journal:  Head Neck Pathol       Date:  2021-06-11

6.  HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Kristian Egebjerg; Cecilie Dupont Harwood; Nina Claire Woller; Claus Andrup Kristensen; Morten Mau-Sørensen
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.